These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 18382153)
21. [Selection and use of anti-infective agents for intra-abdominal infections]. Coelho JC; Baretta GA; Okawa L Arq Gastroenterol; 2007; 44(1):85-90. PubMed ID: 17639190 [TBL] [Abstract][Full Text] [Related]
22. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China. Zhou QT; He B; Zhu H Value Health; 2009; 12(1):40-6. PubMed ID: 18637052 [TBL] [Abstract][Full Text] [Related]
23. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Edelsberg J; Berger A; Schell S; Mallick R; Kuznik A; Oster G Surg Infect (Larchmt); 2008 Jun; 9(3):335-47. PubMed ID: 18570575 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ; BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956 [TBL] [Abstract][Full Text] [Related]
25. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia]. Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176 [TBL] [Abstract][Full Text] [Related]
26. [A method to determine hospital costs associated with nosocomial infections]. Gianino MM; Vallino A; Anselmo E; Minniti D; Abbona F; Mineccia C; Silvaplana P; Zotti CM Ann Ig; 2007; 19(4):381-92. PubMed ID: 17937330 [TBL] [Abstract][Full Text] [Related]
27. Trends in antibiotic use and cost and influence of case-mix and infection rate on antibiotic-prescribing in a long-term care facility. Mylotte JM; Neff M Am J Infect Control; 2003 Feb; 31(1):18-25. PubMed ID: 12548253 [TBL] [Abstract][Full Text] [Related]
28. Transitional (intravenous to oral) antibiotic therapy. Quintiliani R; Grant E; Quintiliani R J Med Liban; 2000; 48(4):233-40. PubMed ID: 11214195 [TBL] [Abstract][Full Text] [Related]
29. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: a prospective, matched analysis. Rosenthal VD; Guzman S; Migone O; Safdar N Am J Infect Control; 2005 Apr; 33(3):157-61. PubMed ID: 15798670 [TBL] [Abstract][Full Text] [Related]
30. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community]. Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168 [TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Paladino JA; Fell RE Ann Pharmacother; 1994 Mar; 28(3):384-9. PubMed ID: 8193431 [TBL] [Abstract][Full Text] [Related]
32. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia. Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142 [TBL] [Abstract][Full Text] [Related]
33. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787 [TBL] [Abstract][Full Text] [Related]
34. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Nicasio AM; Eagye KJ; Kuti EL; Nicolau DP; Kuti JL Pharmacotherapy; 2010 May; 30(5):453-62. PubMed ID: 20411997 [TBL] [Abstract][Full Text] [Related]
35. Cost of Gram-negative resistance. Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346 [TBL] [Abstract][Full Text] [Related]
37. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study]. Marcellusi A; Viti R; Incorvaia C; Mennini FS Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978 [TBL] [Abstract][Full Text] [Related]
38. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J; Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979 [TBL] [Abstract][Full Text] [Related]
39. Economic impact of a rational use of antibiotics in intensive care. Blanc P; Von Elm BE; Geissler A; Granier I; Boussuges A; Durand Gasselin J Intensive Care Med; 1999 Dec; 25(12):1407-12. PubMed ID: 10660849 [TBL] [Abstract][Full Text] [Related]
40. Antimicrobial stewardship: bridging the gap between quality care and cost. Goff DA Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]